BioVaxys Technology Corp.
BVAXF
$0.0389
$0.00010.26%
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 145.21% | -6.33% | -40.55% | 7.84% | -44.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.99% | -8.67% | -50.77% | -7.03% | -59.62% |
| Operating Income | -122.99% | 8.67% | 50.77% | 7.03% | 59.62% |
| Income Before Tax | 59.08% | 63.65% | 154.10% | 57.96% | -198.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.08% | 63.65% | 154.10% | 57.96% | -198.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.08% | 63.65% | 154.10% | 57.96% | -198.67% |
| EBIT | -122.99% | 8.67% | 50.77% | 7.03% | 59.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.92% | 77.38% | 141.94% | 69.31% | -100.00% |
| Normalized Basic EPS | 84.43% | 52.00% | 69.23% | -235.00% | -171.11% |
| EPS Diluted | 72.92% | 77.38% | 141.94% | 69.31% | -100.00% |
| Normalized Diluted EPS | 84.43% | 52.00% | 69.23% | -235.00% | -171.11% |
| Average Basic Shares Outstanding | 49.90% | 59.58% | 27.39% | 37.16% | 49.90% |
| Average Diluted Shares Outstanding | 49.90% | 59.58% | 27.39% | 37.16% | 49.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
